Cluster Headache Syndrome - Pipeline Insight, 2024

This “Cluster Headache Syndrome- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Cluster Headache Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cluster Headache Syndrome: Understanding

Cluster Headache Syndrome: Overview

Cluster headaches are rare when compared to other types of headaches. The pain they produce is severe and tends to recur in the same way each time. They occur in groups, or clusters, and each attack lasts about 1 to 3 hours on average. The frequency of occurrence may range from every other day to multiple times a day. Cluster periods are followed by remissions that may last months or years. Males are affected by cluster headaches more than females and they typically start around age 30. Researchers do not know exactly what causes cluster headaches. They seem to be related to the sudden release of histamine or serotonin in the body. The following may trigger cluster headaches: Alcohol use or smoking cigarettes, change to a high altitude, bright light, exercise or exertion, heat, either weather or a bath, foods that contain nitrates, such as bacon or lunch meat and Cocaine use. These are common symptoms of a cluster headache: Sudden onset of pain, generally around or behind the eye, pain builds to a peak in about 10 to 15 minutes, restlessness or agitation, red or watering eyes, nasal congestion, sweating on the forehead and eyelid drooping or swelling. A two-pronged approach is necessary for treatment of cluster headaches: aborting an attack and preventing future attacks. To stop or at least subdue an attack in progress, patient may be given high-dose oxygen therapy through a face mask for 15 to 20 minutes. The doctor may also prescribe a nasal spray called sumatriptan to relieve the severe pain of a cluster headache. Sumatriptan is a selective serotonin receptor agonist. This medicine causes blood vessels in the brain to constrict, thereby relieving pain. The second part of cluster headache treatment is to prevent recurrent attacks by using daily medicine. Several medicines are used to prevent cluster headache attacks: Verapamil. A medicine that relaxes blood vessels, Prednisone. A steroid that reduces inflammation and swelling and Lithium carbonate. A medicine that restores the balance of certain brain chemicals. A true cluster headache is not life threatening and does not cause permanent brain damage. But, they tend to be chronic, recurrent, and can interfere with your lifestyle or work. To prevent a cluster headache, it's important to identify what triggers headaches. Avoiding smoking and alcohol use provides a greater relief to the patient population.

Cluster Headache Syndrome- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cluster Headache Syndrome pipeline landscape is provided which includes the disease overview and Cluster Headache Syndrome treatment guidelines. The assessment part of the report embraces, in depth Cluster Headache Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cluster Headache Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cluster Headache Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Cluster Headache Syndrome.

Cluster Headache Syndrome Emerging Drugs Chapters

This segment of the Cluster Headache Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cluster Headache Syndrome Emerging Drugs

Eptinezumab: Lundbeck Seattle Bio Pharmaceuticals Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP a- and ß-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache. Currently, the drug is being developed in the Phase III stage of clinical trial evaluation for the treatment of Cluster HeadacheSyndromes.

SYNP-101: Ceruvia Lifesciences SYNP-101 is a synthetic form of the naturally occurring compound, psilocybin, found in at least 200 species of mushrooms. Currently, the drug is being developed in the Phase I stage of clinical trial evaluation for the treatment of Cluster HeadacheSyndromes.

Cluster Headache Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Cluster Headache Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cluster Headache Syndrome

There are approx. 5+ key companies which are developing the therapies for Cluster Headache Syndrome. The companies which have their Cluster Headache Syndrome drug candidates in the most advanced stage, i.e. phase III include, Lundbeck Seattle BioPharmaceuticals.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cluster Headache Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cluster Headache Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cluster Headache Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cluster Headache Syndrome drugs.

Cluster Headache Syndrome Report Insights

• Cluster Headache Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cluster Headache Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cluster Headache Syndrome drugs?
• How many Cluster Headache Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cluster Headache Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cluster Headache Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cluster Headache Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lundbeck Seattle BioPharmaceuticals
• Ceruvia Lifesciences

Key Products

• Eptinezumab
• SYNP-101
• NYPRG101

This product will be delivered within 2 business days.